The influence of administration of epoetin beta pegol (CERA) and saccharated ferric oxide on erythroferron and hepcidin of hemodialyzed patients

Trial Profile

The influence of administration of epoetin beta pegol (CERA) and saccharated ferric oxide on erythroferron and hepcidin of hemodialyzed patients

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2015

At a glance

  • Drugs Methoxy polyethylene glycol-epoetin beta (Primary)
  • Indications Anaemia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 27 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top